|
Hi,
I think the real question is whether or not bisphosphanates are going to become standard of care for early-stage bc patients for prevention of bone mets. As it stands, this type of therapy is only available off-label/protocal for prevention of mets for early-stagers. Has anyone heard anything different given the study that was posted?
Jen
|